FDA conducts inspection of Sightlife in Seattle on Nov. 18, 2024
The FDA conducted an inspection at Sightlife in Seattle on November 18, 2024, focusing on human cellular, tissue, and gene therapies.

The FDA conducted an inspection at Sightlife in Seattle on November 18, 2024, focusing on human cellular, tissue, and gene therapies.

On January 12, 2024, the Food and Drug Administration conducted a bioresearch monitoring inspection of David Dale, M.D. in Seattle, according to information available on the FDA’s website.

The FDA conducted an inspection at Immunexpress, Inc. in Seattle on December 6, 2024, focusing on device compliance and post-market surveillance.

On February 16, 2024, the FDA conducted an inspection of UW Medicine – University of Washington in Seattle focusing on blood and blood products, according to information available on the FDA’s website.

The FDA conducted an inspection at Jones Soda Company in Seattle on June 13, 2024, focusing on foodborne biological hazards.

The FDA conducted a bioresearch monitoring inspection at Suman Jayadev, M.D. in Seattle on September 12, 2024.

Genre Foods, LLC in Seattle underwent an FDA inspection on January 17, 2024, focusing on foodborne biological hazards, according to information available on the FDA’s website.

On August 23, 2024, All the Best Pet Care in Seattle underwent an FDA inspection focusing on the monitoring of marketed animal drugs, feed, and devices, according to information available on the FDA’s website.

The Food and Drug Administration (FDA) conducted a bioresearch monitoring inspection of Ashley E. Fuller, M.D. in Seattle on March 6, 2024, according to information available on the FDA’s website.

The FDA conducted an inspection at Pescamax, Inc. in Seattle on September 5, 2024, focusing on foodborne biological hazards.